Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease: a systematic review

Susan Kenneally,¹ Joanna H Sier,² J Bernadette Moore^{1,2}

To cite: Kenneally S, Sier JH, Moore JB. Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease: a systematic review. *BMJ Open Gastro* 2017;4:e000139. doi:10.1136/bmjgast-2017-000139

SK and JHS are joint first authors.

This protocol was registered at PROSPERO database (<https://www.crd.york.ac.uk/PROSPERO/>) as CRD42016032764 (https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016032764).

Received 18 February 2017
Revised 21 April 2017
Accepted 27 April 2017

¹Department of Nutritional Sciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK

²School of Food Science and Nutrition, University of Leeds, Leeds, West Yorkshire, UK

Correspondence to
Dr J Bernadette Moore;
j.b.moore@leeds.ac.uk

ABSTRACT

Background: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide, with prevalence above 30% in many adult populations. Strongly associated with obesity, weight loss through diet and physical activity is the mainstay of its management. Weight loss can be difficult to achieve and maintain however, and uncertainty exists as to which lifestyle changes are most effective.

Objective: The aim of this work was to systematically evaluate randomised controlled trials assessing diet, exercise or combination interventions aimed at reducing steatosis or markers of NAFLD activity.

Design: Medline, Scopus and Cochrane databases were searched from 1 January 1980 through to 31 July 2016, for intervention trials assessing the effects of diet, weight loss, exercise or any combination thereof, on NAFLD disease markers in human adults. Risk of publication bias and study quality was assessed using the American Dietetic Association Quality Criteria Checklist.

Results: From a total of 1710 identified records, 24 articles met the inclusion and exclusion criteria; 6 assessed weight loss using dietary restriction, 10 assessed exercise and 8 were combination interventions. While all of the trials demonstrated significant reduction in steatosis and/or markers of NAFLD activity, combination interventions appear to be the most effective at improving NAFLD. Results suggest that 5–10% weight loss using a modestly hypocaloric diet of 500 kcal less per day than calculated energy requirement, in combination with 30–60 min exercise on 3–5 days per week should be recommended.

Conclusions: We conclude this amount of weight loss is achievable in the trial setting but is challenging in the clinical environment. High-intensity, multidisciplinary intervention in specialist clinics is likely to be required in order to manage NAFLD by lifestyle modification alone. This systematic review protocol was registered prospectively at PROSPERO as CRD42016032764.

INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver pathology, strongly associated with obesity and diabetes. Described

as the hepatic component of metabolic syndrome, NAFLD is now the most common cause of chronic liver disease worldwide.¹ Prevalence estimates vary depending on population and ethnicity, but current data suggest prevalence may be as high as 45% of the adult population in many countries.² While the majority of people affected have simple steatosis, which confers a relatively low risk, up to 50% of patients with NAFLD will develop complications including steatohepatitis, fibrosis, cirrhosis and end-stage liver failure or hepatocellular carcinoma.³

Determining the precise incidence and prevalence of NAFLD is problematic as NAFLD is generally an incidental finding in the clinical setting, and the lack of a precise and inexpensive diagnostic tool makes population studies on a large scale difficult.¹ A diagnosis of NAFLD can only be made in the absence of significant ethanol intake (<20 g/day in men and 10 g/day in women). In addition, the exclusion of other causes of steatosis, including; hepatitis C, medication, malnutrition, rapid weight loss and inflammatory bowel disease, is also required.^{4–6} Importantly, evidence suggests it is possible to delay or even reverse disease progression in the earlier stages of NAFLD, and many therapeutic agents and nutritional supplements have been studied to this end, with some showing some limited promise in phase II and III clinical trials.⁷ However, currently there is no specific pharmaceutical agent for the treatment of NAFLD, and lifestyle change aimed at weight loss remains the mainstay of clinical management guidelines.^{4–6}

Weight loss and increased physical activity are known to be associated with improvements in other components of metabolic syndrome, possibly by reducing the enhanced inflammatory state associated with the condition.^{8–9} While there is general consensus that many types of lifestyle interventions should

be effective in reducing steatosis and improving histological markers of disease progression, comparison proves difficult because of the diversity of intervention protocols and NAFLD diagnostic and outcome criteria used in trials.¹⁰ Recent meta-analyses examining exercise interventions suggest positive effects on reduction in alanine aminotransferase (ALT) levels and intrahepatic fat, although the clinical significance of reported standard mean differences can be difficult to interpret.^{11 12} These reviews highlight the considerable heterogeneity in duration and types of exercise intervention employed. While they both conclude a benefit to exercise intervention, some low-quality trials were included and questions about inclusion and exclusion criteria, grouping of studies and the role of diet and weight loss remain.

In this context, the aim of this review was to systematically evaluate the existing randomised controlled trials (RCTs) assessing the effects of interventions involving diet, weight loss, exercise or any combination thereof, on biochemical, radiological or histological markers of NAFLD in adults. It was hypothesised that weight loss and exercise interventions would be effective, and that combination interventions would be more effective than weight loss or exercise alone.

METHODS

Methods of the analysis and eligibility criteria were specified prior to the literature search and documented in a protocol registered with Prospero (CRD42016032764). The review was conducted by SK according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines¹³ including independent execution of search strategy and bias assessment, completed by JS; third-party adjudication was done by JBM. The PubMed, Scopus and the Cochrane databases were searched from 1 January 1980 to 31 July 2016. The search terms were 'NAFLD and exercise', 'NAFLD and weight loss' and 'NAFLD and diet/diet, reducing' for PubMed and Scopus, and 'NAFLD' for the Cochrane database. The searches were limited to clinical trials, human studies, English language and journal articles where possible.

RCTs in human adults of any gender/ethnicity with a diagnosis of NAFLD, non-alcoholic steatohepatitis (NASH), fibrosis or NAFLD-based cirrhosis made on validated biochemical, radiological or histological evidence were included; other causes of fatty liver disease were excluded. Papers excluded from this review were: non-human studies, letters/case reports, studies relating to children, articles not reporting primary outcomes of interest or primary data reporting, and trials using non-invasive methods that have not been validated. Included trials had to have measured as primary outcomes either: changes in biochemical, radiological or histological markers of NAFLD in response to a diet, weight loss or exercise (or combination of these) intervention. The validity of eligible RCTs was assessed

using the American Dietetic Association (ADA) quality assessment tool.¹⁴

Information was recorded from each included trial, specifically: (1) the aim of the intervention; (2) the method of recruiting participants; (3) the inclusion and exclusion criteria for the study; (4) whether or not informed consent was obtained; (5) whether or not ethics approval had been sought and granted; (6) any funding sources; (7) the statistical methods used to analyse the data; (8) methods of randomisation; methods of allocation concealment; blinding of participants and personnel where appropriate; blinding of the outcome assessment; (9) incomplete outcome data reporting; any selective reporting and other sources of bias as detailed in the Cochrane handbook.¹⁵

In addition, further information recorded from each trial included: the principal and secondary outcome measures as identified by the authors; the methods of assessing outcome measures; the validity and reliability of the outcome measures; the methods of follow-up for non-respondents; the timing of the outcome assessment and any adverse events. The primary measures of the treatment effects were relative reduction in markers of NAFLD compared with controls. These included degree of steatosis on imaging, levels of biochemical markers of NAFLD, histological assessment of NAFLD activity score (NAS) and change in biochemical indices aimed at assessing degree of NAFLD, for example, the fatty liver index (FLI) or the visceral adiposity index (VAI).

RESULTS

Search results

The identification and selection of eligible studies included in this review are illustrated in figure 1. Database searches returned 1979 citations with 269 included in more than one search. Following removal of duplicates, 1710 citations remained. These publications were screened for eligibility by reading the abstracts and those not meeting the eligibility criteria were excluded. Papers excluded were either animal studies, drug/supplementation trials, review papers, trials done in children and trials that were not randomised and/or controlled, trials not assessing NAFLD markers as a primary outcome and non-English articles. This resulted in 43 trials which, based on reading the abstracts, met the inclusion criteria for this review. The papers reporting these trials were then read in full. Following this, a further 19 trials were excluded, for the following reasons: five were not randomised; three had no control or cointervention group; five did not require a diagnosis of NAFLD as an inclusion requirement; one included subjects with hepatitis C so did not meet the exclusion criteria. Two were retrospective studies and three evaluated a primary outcome that was not related to NAFLD. Five trials did not specify NAFLD as an inclusion criterion, but did assess and report change in NAFLD as a main outcome and were included.^{16–20}

Figure 1 Flow diagram showing identification and selection of relevant studies for inclusion in this systematic review.

Trial characteristics

Overall, 2322 individuals participated in a total of 24 trials with durations ranging from 2 weeks to 1 year. Of the 24 trials that met the inclusion and exclusion criteria, 6^{20–25} assessed weight loss through dietary modification (table 1), 10^{16–19 26–31} assessed exercise (table 2), and 8^{32–39} investigated the effects of a combination of diet and exercise (table 3).

The protocols for the interventions were diverse. The trials assessing dietary intervention alone were all hypocaloric but reductions in food intake ranged from a mild decrease of 200 kcal/day²⁴ to a very low calorie diet (VLCD) with a total intake of 450 kcal/day.²⁰ Dietary compositions were different for each of the 6 interventions. The majority of exercise interventions were various forms of aerobic exercise such as cycling ergometer^{16 18} or walking at high intensity;¹⁹ however three studies considered the effects of differing resistance exercise regimes alone^{27 29 30} while the protocol for one involved counselling alone, aimed at increasing physical activity.²⁶ Similarly, there was considerable heterogeneity among the combination interventions.

Inclusion and exclusion criteria also varied; of the 24 trials, 10 specified overweight or obesity as a requirement.^{16 18–20 22 28 34–36 39} Diabetes status was sometimes an inclusion criterion^{16 17} but more often a reason for exclusion.^{18 20 22 24 28 29 32} The majority of trials included participants of both genders (age 18–75), with the percentage

participation of each sex varying across the studies, although a minority included exclusively male³⁶ or female³⁵ subjects. Five interventions involving exercise also excluded those who were physically unable to complete the protocol.^{17 29 30 32 34} All but one of the interventions assessing exercise without dietary modification required participants to have been sedentary prior to the intervention.³⁰ The trials took place in a wide range of geographical locations; however, only four studies specified ethnicity as an inclusion/exclusion criterion.^{16 17 20 33}

By our review criteria, outcome measures always included changes in hepatic markers. However, associated or secondary outcomes varied markedly between studies, with some assessing only liver outcomes while others also reported data relating to weight, body mass index, glucose metabolism, cardiovascular fitness and other markers linked with NAFLD. The methods of diagnosing and measuring change in NAFLD were also heterogeneous, the most common being MRI/magnetic resonance spectroscopy (MRS) in eight of the studies;^{16 18 19 23 27 28 33 38} three trials required a biopsy;^{21 34 37} five assessed NAFLD using ultrasound;^{20 29 31 32 35} five were based on liver biochemistry,^{17 22 26 36 39} two on ultrasound and liver biochemistry^{24 31} and one on the Asian Working Party Guidelines for the diagnosis of NAFLD.^{30 40} One paper excluded those with simple steatosis and assessed only participants with steatohepatitis.³⁴

Table 1 Trials evaluating dietary intervention alone on NAFLD-related outcomes

Author (year); country	Intervention	Age range; sample size (% male)	Study duration	Outcome measures	Changes to outcome measures postintervention
Yamamoto (2007); ²¹ Japan	Low calorie (126 kJ/kg/d), low fat (20%), low iron (≤ 6 mg/d) and 1.1–1.2 g/kg/d protein	37–74; 27 (52%)	6 months	<i>Primary:</i> AST, ALT <i>Other:</i> WT, BMI, TG, TC, GLC, Iron, FER, TS	<i>Primary:</i> ↓ AST* ↓ ALT* ↓ WT* (4.8%) and ↓ BMI*
Lin (2009); ²⁰ Taiwan	VLCD of 450 kcal/day or 800 kcal/day	18–65; 132 (34%)	12 weeks	<i>Primary:</i> NAFLD (ultrasound) resolution and improvement <i>Other:</i> WT, BMI, WC, FM, GLC, BP, TG	95 completed trial; NAFLD resolved in 5 cases (450 kcal group) and 10 cases (800 kcal group) NAFLD improved in 17 cases (450 kcal group) and 21 cases (800 kcal group) ↓ WT* 9.14% (450 kcal/day), ↓ 8.98% (800 kcal/day), and ↓ BMI*
De Luis (2010); ²² Spain	Low fat, low calorie (1500 kcal/day, 27% fat/53% CHO) or low CHO, low calorie diet (1507 kcal/day, 38% CHO/36% fat)	29–64; 162 (29%)	3 months	<i>Primary:</i> AST, ALT <i>Other:</i> WT, BMI, BP, TC, HDL, LDL, TG, FM, WC, WHR, GLC, INS, HOMA	Low fat (NAFLD): ↓ AST* ↓ ALT* ↓ WT* (3.9%) and ↓ BMI* Low-CHO diet (NAFLD): ↓ AST* ↓ ALT* ↓ WT* (4.9%) and ↓ BMI*
Browning (2011); ²³ USA	Low CHO (<20 g/d) or low calorie (1200–1500 kcal/d)	33–57; 18 (27%)	2 weeks	<i>Primary:</i> IHTG (MRS), AST, ALT <i>Other:</i> WT, BMI, TC, TG, GLC	↓ IHTG* 28% (low cal), 55% (low CHO); ↓ AST*; ↑ ALT§; ↓ BMI* ↓ WT* (4.2% low cal and 4.7% low CHO) and ↓ BMI*
Kani (2014); ²⁴ Iran	Calorie restriction (200–500 kcal/day; 55% CHO, 15% protein, 30% fat) Calorie restriction, low CHO (45% CHO, 20% protein, 35% fat) Calorie restriction, low CHO + 30 g soy protein	43–52; 45 (46%)	8 weeks	<i>Primary:</i> AST, ALT <i>Other:</i> WT, BMI, INS, TG, TC, HDL, LDL, ALP, FIB, MDA	↓ AST* and ALT* in all groups; greatest reduction seen in the soy group. All diets saw ↓ WT*: 3.9%, 4.2%, 4.7%, respectively and ↓ BMI*
Razavi Zade (2016); ²⁵ Iran	Calorie restriction (350–700 kcal) or Calorie restriction and DASH diet (rich in fruit, veg, whole grains and low fat dairy; low in saturated fats, cholesterol and sugar)	25–75; 60 (50%)	8 weeks	<i>Primary:</i> Steatosis grade (ultrasound), AST, ALT <i>Other:</i> WT, VLDL, LDL, HDL	Steatosis grade improved on both diets; more cases improved on DASH (80% vs 43%)* ↓ AST* ↓ ALT* with DASH not low cal ↓ WT* (3.0% low cal and 4.6% DASH)

*Statistically significant; §No statistical difference.

ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index (kg/m²); BP, blood pressure; CHO, carbohydrate; DASH, dietary approaches to stop hypertension; FER, ferritin; FIB, serum fibrinogen; FM, fat mass; GLC, glucose; HDL, high-density lipoprotein; HOMA, Homeostasis Model Assessment; IHTG, intrahepatic triglyceride; INS, insulin; LDL, low-density lipoprotein; MDA, malondialdehyde; MRS, magnetic resonance spectroscopy; NAFLD, non-alcoholic fatty liver disease; NMR, nuclear magnetic resonance; TC, total cholesterol; TG, triglyceride; TS, transferrin saturation; VLCD, very low calorie diet; VLDL, very low density lipoprotein; WC, waist circumference; WHR = waist:hip ratio; WT, weight.

Table 2 Trials evaluating exercise intervention alone on NAFLD-related outcomes

Author (year); country	Intervention	Age range; sample size (% male)	Study duration	Outcome measures	Changes to outcome measures postintervention
Johnson (2009), ¹⁸ Australia	Cycle ergometer 30–45 min 3x/week, increasing from 50–70% pretraining VO ₂ max	43–51; 23 (65%)	4 weeks	<i>Primary:</i> IHTG, SI, ALT <i>Other:</i> WT, BMI, Cholesterol, IMTG, SAT, VAT	↓ IHTG* 1.76% No significant change SI, ALT, WT, BMI ↓ VAT*
St George (2009), ²⁶ Australia	Counselling sessions; low-intensity: 3 fortnightly consultations; moderate-intensity: 2 groups received 6 fortnightly consultation, with 1 group receiving additional telephone support	35–60; 141 (61%)	3 months	<i>Primary:</i> ALT, AST <i>Other:</i> WT, BMI, LDL, HDL, GLC, TC, TG, GGT, physical activity	↓ ALT*, and ↓ AST* in all groups, greatest seen in moderate-intensity intervention ↓ WT* and ↓ BMI*, greatest in moderate-intensity intervention
Hallsworth (2011), ²⁷ UK	Resistance exercise 45–60 min, 3x/week	33–72; 21 (NS)	8 weeks	<i>Primary:</i> IHTG (MRS), ALT <i>Other:</i> WT, BMI, WC, HC, WHR, TC, TG, HbA1C, VAT, SAT, FM, GLC, INS, HOMA-IR	↓ IHTG* 13%; 3 participants moved from clinical NAFLD to normal (<5% IHTG) No change ALT, WT, BMI
Sullivan (2012), ²⁸ USA	Brisk walk 30–60 min, 5x/week	44–51; 18 (38%)	16 weeks	<i>Primary:</i> IHTG (MRS), ALT <i>Other:</i> WT, BM, FM, FFM, VO ₂ peak, TC, HDL, LDL, TG, FFA, VLDL	↓ IHTG* 10.3%, ↓ ALT* No change WT
Bacchi (2013), ¹⁶ Italy	Aerobic exercise (AER) at 60% VO ₂ max, 60 min 3x/week or, resistance exercises (RES) 60 min, 3x/week	54–58; 31 (70%)	4 months	<i>Primary:</i> IHTG (MRI), ALT, AST <i>Other:</i> BMI, HbA1c, GGT, TC, LDL, HDL, TG, FFM, IATG, SAT	↓ IHTG* ~35% in both groups; hepatic steatosis resolved in 3 AER and 4 of RES participants ↓ BMI* in both groups No change ALT, AST
Zelber-Sagi (2014), ²⁹ Israel	Resistance training (RT) 40 min 3x/week or, stretching exercises 3x/week	35–57; 82 (53%)	3 months	<i>Primary:</i> HRI score (ultrasound), ALT, AST <i>Other:</i> WT, BMI, BP, GLC, INS, HOMA, TC, TG, HbA1C, HDL, LDL, GGT, FER	↓ HRI score* 11% in RT group ↓ WT* and ↓ BMI* compared with stretching No change ALT, AST
Keating (2015), ¹⁹ Australia	Cycling ergometer and walking at either high intensity/low volume, 45 min 3x/week (HI/LO); low intensity/high volume, 60 min 4x/week (LO/HI); or low intensity/low volume, 45 min 3x/week (LO/LO)	25–59; 48 (35%)	8 weeks	<i>Primary:</i> IHTG (MRS), ALT, AST, SI, WT, BMI <i>Other:</i> WT, BMI, BP, WC, VO ₂ max, TG, TC, HDL, LDL, FFA, INS, GLC, VAT	↓ IHTG* 2.4% (HI:LO), 2.6% (LO:HI), 0.8% (LO:LO) ↓ WT* 1.3% (HI:LO), 1.5% (LO:HI); ↓ BMI*
Balducci (2015), ¹⁷ Italy	Low-intensity resistance and aerobic exercise 2x/week or; high-intensity resistance and aerobic exercise 2x /week	Age NS; 606 (58%)	12 months	<i>Primary:</i> AST, ALT, FLI <i>Other:</i> BMI, VAI, GGT, TG, WC, HOMA-IR, HbA1c	No change ALT, AST, SI ↑ AST*, ↑ ALT*, in exercise and control groups ↓ FLI*, ↓ BMI*, ↓ VAI* in exercise group*

Continued

Table 2 Continued

Author (year); country	Intervention	Age range; sample size (% male)	Study duration	Outcome measures	Changes to outcome measures postintervention
Takahashi (2015); ³⁰ Japan	Regular resistance exercise 20–30 min 3x/week (RES) or education programme on benefits of dietary restrictions and regular physical activity	36–68; 53 (35%)	12 weeks	Primary: Steatosis (ultrasound), AST, ALT Other: FM, MM, LDL, HDL, TG, ALP, GGT, FER, GLC, INS, HOMA-IR, HbA1c	Primary: ↓ steatosis* in RES group No change AST, ALT, WT, BMI
Cuthbertson (2016); ³¹ UK	Supervised moderate-intensity aerobic exercise progressing from 30 min 3x/week to 45 min 5x/week (AER) or control of conventional counselling	50 years (AER) 52 years (Ctrl) 50 (78%)	16 weeks	Primary: IHCL (MRS), AST, ALT Other: WT, BMI, BP, TC, LDL, HDL, VO ₂ max	Primary: ↓ IHCL* 48% in AER only; ↓ AST*, ↓ ALT* in both; greatest in AER ↓ WT* and ↓ BMI* in AER group

*Statistically significant.

ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass; BMI, body mass index (kg/m²); BP, blood pressure; FER, ferritin; FFA, free fatty acids; FFM, fat free mass; FLI, Fatty Liver Index; FM, fat mass, GGT, gamma glutaryl transferase; GLC, glucose; HbA1c, glycosylated haemoglobin; HC, hip circumference; HDL, high-density lipoprotein; HOMA-IR, Homeostasis Model Assessment-Insulin Resistance Index; HRI, hepatorenal-ultrasound index; IATG, intra-abdominal triglyceride; IHCL, intrahepatic triglyceride; IHTG, intrahepatic triglyceride; IMTG, intramyocellular triglyceride; INS, insulin; LDL, low-density lipoprotein; MM, muscle mass; MRS, magnetic resonance spectroscopy; NAFLD, non-alcoholic fatty liver disease; NS, not stated; SAT, subcutaneous adipose tissue; SI, hepatic lipid saturation index; TC, total cholesterol; TG, triglyceride; VAT, visceral adipose tissue; VLDL, very low density lipoprotein; VO₂ max, peak oxygen consumption (mL/kg/min); WC, waist circumference; WHR, waist:hip ratio; WT, weight.

Dietary interventions

Six trials assessing the effects of dietary intervention on NAFLD were identified from: Japan,²¹ Taiwan,²⁰ Spain,²² USA²³ and Iran.^{24–25} Interventions were heterogeneous (table 1) and ranged in duration from 2 weeks to 6 months. Notably five of the six dietary interventions reported liver enzymes and all saw reductions in these after intervention. All measured a weight loss from dietary changes, with most achieving 3.0–4.9%, with the exception of the VLCD trial carried out by Lin *et al*²⁰ where participants only consumed 450 kcal/day or 800 kcal/day. This intervention saw larger weight losses of 9.14% and 8.98%, respectively; with 5 and 10 cases of NAFLD being completely resolved, as assessed by ultrasound. Three of the interventions measured NAFLD severity by ultrasound or nuclear magnetic resonance, and only Lin *et al*²⁰ saw cases resolved; whereas a more moderate calorie restriction diet carried out by Browning *et al*²³ saw NAFLD improvement with a 28% intrahepatic triglyceride (IHTG) reduction; and Razavi *et al*²⁵ using a calorie-restricted, dietary approaches to stop hypertension (DASH) diet resulted in 10 participants moving from grade III to II NAFLD and 20 from grade II to I, as assessed by MRS.

Exercise interventions

Ten RCTs assessing the effects of exercise on NAFLD were identified from: Australia,^{18–19–26} UK,^{27–31} USA,²⁸ Italy,^{16–17} Israel²⁹ and Japan.³⁰ Interventions ranged from 4 weeks to 12 months (table 2). Eight trials examined the effects of aerobic exercise, in comparison to a more sedentary lifestyle with only standard care implemented, resulted in improvements in NAFLD^{17–19–26–28–30–31} as measured by reduced levels of hepatic enzymes ALT and aspartate aminotransferase (AST). Six of the 10 interventions also measured and reported percentage change in IHTG content by either proton MRS (H-MRS)^{19–27–28–31} or MRI.^{16–18} This ranged from 1.76–48%, with the smallest percentage change being associated with the shortest duration intervention of 4 weeks,¹⁸ and the largest change being a trial of longer duration at 4 months.³¹ The interventions carried out by Bacchi *et al*¹⁶ and Cuthbertson *et al*³¹ were both 4 months (16 weeks) in duration with cohorts of similar age and both supervised in exercise achieving 48% and 35% reduction in % IHTG, respectively. However the Bacchi trial defined all three exercise sessions per week as supervised, and the Cuthbertson trial saw participants attend the gym weekly and were monitored through the wellness system which tracked exercise within designated facilities; so the results could be indicative of the beneficial role of direct supervision, in the form of personal trainers.

Combination interventions

Eight trials that assessed the effects of a combination of dietary and exercise interventions were identified from: Taiwan,³² Germany,³³ USA,^{34–37} Mexico,³⁵ Hong Kong³⁸ and Spain³⁹ (table 3). These trials ranged in durations

Table 3 Trials evaluating combination of exercise and dietary intervention on NAFLD outcomes

Author (year); country	Intervention	Age range; sample size (% male)	Study duration	Outcome measures	Changes to outcome measures postintervention
Chen (2008), ³² Taiwan	Hypocaloric diet 1200–1500 kcal/day and 1 hour 2x/week on stationary cycle (diet and exercise group, DPE); or exercise only group (E)	29–46; 54 (62%)	10 weeks	<i>Primary:</i> Steatosis grade (ultrasound), AST, ALT <i>Other:</i> WT, BMI, WC, HC, TC, TG, HDL, LDL, GLC, INS, HOMA-IR, GGT, CVE, HR	↓ steatosis* grade both groups ↓ AST* and ↓ ALT*, greatest in DPE ↓ WT* and ↓ BMI both groups*, greatest in DPE group (6.3% vs. 0.9% in E)
Kantartzis (2009), ³³ Germany	Dietary counselling consisting of 10 sessions with dietitian and asked to perform 3 hours moderate exercise/week (eg, walking, swimming)	19–68; 170 (41%)	9 months	<i>Primary:</i> IHTG (MRS), AST, ALT <i>Other:</i> BMI, WC, FM, SAT, VAT, GLC, INS, VO ₂ max	↓ IHTG* 35.2%; 20 of 50 NAFLD cases were resolved at follow up ↓ AST*, and ↓ ALT* ↓ BMI*, and ↓ VAT*, ↓ NAS*, greatest change seen in intensive intervention(–2.4 vs. –1.4 in control)
Promrat (2010), ³⁴ USA	1000–1500 kcal/day (25% fat), moderate intensity exercise progressing to 200 min/week with weekly (first 6 months) then biweekly health education sessions; or basic education sessions (every 12 weeks) on healthy eating, physical activity and weight control	34–59; 31 (59%)	48 weeks	<i>Primary:</i> NAS (liver biopsy), AST, ALT <i>Other:</i> WT, BMI, TG, LDL, HDL, GLC, INS, HbA1C, HOMA	↓ AST [§] , ↓ ALT*, (greatest change seen in intensive intervention‡ See ↓ AST but no significant difference between the two treatment groups ↓ WT* (8.8% in intensive vs. 0.5%) and ↓ BMI* ↓ AST* and ↓ ALT* in both groups, but no difference between diets. ↓ WT* (5.7% low cal, 5.5% low fat) and ↓ BMI*
Rodriguez-Hernandez (2011), ³⁵ Mexico	Low calorie (30 kcal/kg/day), low CHO (27% protein, 28% fat, 45% CHO) plus 5 hours exercise/week; or an isocaloric, low fat (21% fat, 25% protein, 54% CHO) with same exercise	20–65; 59 (0%)	6 months	<i>Primary:</i> AST, ALT <i>Other:</i> WT, BMI, FM, GLC, TC, TG	↓ AST* and ↓ ALT* in diet plus exercise group ↓ BMI* in AER group
Al-Jiffri (2013), ³⁶ Saudi Arabia	1200 calories/day (15% protein, 30–35% fat, 50–55% CHO) plus aerobic exercise 30 min 3x/week	35–55 100 (100%)	3 months	<i>Primary:</i> AST, ALT <i>Other:</i> BMI, GGT, HOMA-IR, ALP	

Continued

Table 3 Continued

Author (year); country	Intervention	Age range; sample size (% male)	Study duration	Outcome measures	Changes to outcome measures postintervention
Eckard (2013); ³⁷ USA	Low-fat diet (20% fat, 60% CHO, 20% protein) with moderate exercise (20–60 min 4–7 days/week); moderate-fat/low CHO diet (30% fat, 50% CHO, 20% protein) with moderate exercise; or moderate exercise only	18–70; 41 (61%)	6 months	<i>Primary:</i> NAS (liver biopsy), AST, ALT <i>Other:</i> WT, BMI, LDL, HDL, TG, ALP, INS, GLC	↓ NAS* in both diet and exercise combination groups (–1.3 low fat, –1.2 low CHO) ↓ AST [§] and ↓ ALT* in all groups No significant change in WT among groups
Wong (2013); ³⁸ Hong Kong	Weight loss diet supervised by dietitian weekly (4 months) then monthly (8 months) plus moderate-intensity aerobic exercise 30 min 3–5 days/week	42–60; 154 (46%)	1 year	<i>Primary:</i> IHTG (H-MRS), LS, AST, ALT <i>Other:</i> WT, BMI, WC, WHR, GLC, TC, HDL, LDL, TG	↓ IHTG* 54%, 49 of 77 NAFLD cases resolved (<5% IHTG at 1 year) ↓ LS*, ↓ ALT* and ↓ AST [§] ↓ WT* (7.9%) and ↓ BMI*
Aller (2014); ³⁹ Spain	Hypocaloric diet either high MUFA (M; 1342 kcal/day, 21% fat of which 67% MUFA); or high PUFA (P; 1459 kcal/day, 21% fat of which 55% PUFA); with aerobic exercise 60 min 3x/week	32–66; 306 (28%)	3 months	<i>Primary:</i> ALT, AST <i>Secondary:</i> WT, BMI, FM, WC, WHR, GLC, TC, LDL, HDL, TG, INS, HOMA, GGT	↓ ALT* and ↓ AST* in both groups ↓ WT* (4.4% M, 4.7% P) and ↓ BMI* No differences between M and P diets

*Statistically significant.

§No statistically significant difference.

ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index (kg/m²); CVE, cardiovascular endurance; FM, fat mass, GGT, gamma glutaryl transferase; GLC, glucose; HbA1c, glycosylated haemoglobin; HC, hip circumference; HDL, high-density lipoprotein; HOMA, Homeostasis Model Assessment; HOMA-IR, Homeostasis Model Assessment-Insulin Resistance Index; HR, heart rate; IHTG, intrahepatic triglyceride; INS, insulin; LDL, low-density lipoprotein; LS, liver stiffness; MUFA, monounsaturated fat; MRS, magnetic resonance spectroscopy; NAFLD, non-alcoholic fatty liver disease; NAS, NAFLD activity score; PUFA, polyunsaturated fat; SAT, subcutaneous adipose tissue; TC, total cholesterol; TG, triglyceride; VAT, visceral adipose tissue; VO₂ max, peak oxygen consumption (mL/kg/min); WC, waist circumference; WHR, waist:hip ratio; WT, weight.

Figure 2 American Dietetic Association (ADA) Quality Criteria Checklist carried out on the 24 eligible trials. (1) Clear Research Question; (2) Unbiased Selection of Participants; (3) Randomization/Group Comparability; (4) Description of Withdrawals; (5) Blinding; (6) Study Procedures Described; (7) Clearly Defined Outcomes; (8) Appropriate Statistical Analysis; (9) Results Support Conclusion; (10) Funding or Sponsorship Bias Unlikely. To be rated positive, each of criteria 2, 3, 6 and 7 must be met and the majority of 10 criteria overall. Any of criteria 2, 3, 6 and 7 not being met resulted in a neutral rating. The majority of criteria not being met results in a negative rating.

Theme	Author	Validity Questions ¹										Overall Quality rating
		1	2	3	4	5	6	7	8	9	10	
Weight loss	Yamamoto (2007)											Neutral
	Lin (2009)											Positive
	De Luis (2010)											Neutral
	Browning (2011)											Neutral
	Kani (2014)											Positive
	Razavi-Zade											Positive
Exercise	Johnson (2009)											Positive
	St George (2009)											Neutral
	Hallsworth (2011)											Neutral
	Sullivan (2012)											Positive
	Bacchi (2013)											Positive
	Zelber-Sagi											Positive
	Keating (2015)											Positive
	Balducci (2015)											Positive
	Takahashi (2015)											Neutral
	Cuthbertson											Positive
	Chen (2008)											Neutral
	Kantartzis (2009)											Positive
Combination	Promrat (2010)											Positive
	Rodriguez-Hernandez (2011)											Neutral
	Al-Jiffri (2013)											Neutral
	Eckard (2013)											Positive
	Wong (2013)											Positive
	Aller (2014)											Neutral

of 10 weeks to 12 months with two exclusively studying women³⁵ or men.³⁶ They all used a combination of hypocaloric diet and regular aerobic exercise, although protocols varied with some also assessing the benefits of resistance exercise. A 9-month study by Kantartzis *et al*³³ used dietary counselling and moderate physical activity recommendations, which achieved a 35.2% reduction in liver fat (assessed by MRS), and significant changes in hepatic enzyme levels; resulted in 40% of participants seeing NAFLD resolved. Similarly, in the larger cohort of Wong *et al*,³⁸ 154 patients given dietary counselling sessions with aerobic exercise advice over a year, there was a considerable percent change of 54% in IHTG. Other interventions reported the grade of NAFLD rather than % IHTG^{32 34 37} but all measured an improvement in their NAFLD grade or NAS. In the six of eight trials that reported changes in body weight over the course of their interventions, five studies showed weight losses of 4.4–8.8%; with Promrat *et al*³⁴ showing the greatest losses in an intensive 48-week intervention.

Quality assessment

Using the ADA quality assessment criteria (figure 2), 13 of the 24 studies were rated as positive, high-quality trials.^{16–20 24 25 28 29 33 34 37 38} In eight of the trials, insufficient information was provided to make an informed decision regarding the adequacy of randomisation^{21 22 26 27 30 32 35 36} and one trial was described as ‘semi-random’.²³ One trial rated neutral provided insufficient evidence of group comparability,³⁶ two neutral trials had patients studied in two different centres^{20 31} and one

provided insufficient information about the exercise arm of their intervention.³⁵ A number of the trials were rated positive as they met criteria 2, 3, 6 and 7 of the checklist and the majority of the checklist overall, but there were some remaining concerns. In 10 of the trials there was insufficient description of the methods of handling withdrawals from the trial,^{21–23 26 27 32 33 36 39} nine did not provide information regarding blinding where appropriate, in five there were concerns about the statistical analysis,^{22–24 26 33} three provided no discussion of potential limitations^{23 26 36} and eight provided insufficient evidence regarding their funding source^{21–23 33 35 37 39} so that it was not possible to reasonably conclude that the results had not been biased as a result of the funding source. In summary, over 50% of trials were of high quality and those rated as neutral did have a number of positive points.

DISCUSSION

Overall, the evidence from the interventions reviewed suggests that weight loss of 5% in NAFLD or 7–10% in NASH is beneficial, and this should be achieved by a combination of moderate dietary restriction and 30–60 min of moderate-intensity exercise on 3–5 days per week. Moderate-intensity exercise requires moderate effort and noticeable acceleration of the heart rate with some increase in rate of breathing, but the person should still be able to hold a conversation. Moderate-intensity activities include brisk walking, taking stairs, using a cross trainer, gardening or vigorous housework. High-intensity exercise

requires a large effort with substantial increase in heart rate and rapid breathing, for example, running or fast cycling; individuals are considerably less able to hold a conversation. The combination of diet and exercise appears to increase the likelihood of achieving the required weight loss and leads to greater improvements in markers of NAFLD activity; current guidelines reflect this.^{5,6} Interventions which improve insulin resistance also improve markers of metabolic syndrome, and dietary restriction and exercise have been shown to improve insulin resistance in trials included in this review.^{16 22 24 30 32 33 39} However, the relationship may be more complex in that some individuals without insulin resistance or obesity develop NAFLD, and while NAFLD and metabolic syndrome have underlying pathology strongly related to insulin resistance, the relationship may be bi-directional.⁴¹

The results of the dietary interventions included in this review suggest that reductions in body weight lead to significant improvements in NAFLD activity. NAS are calculated based on histological grading of patients' liver steatosis, lobular inflammation and cellular ballooning. The higher the score the greater the NAFLD severity. Four of the trials^{21–24} achieved comparable weight losses of 4% using a moderately hypocaloric diet. The study involving the VLCD²⁰ achieved a greater loss but these type of diets are a unique intervention in their own right and not intended to be a long-term lifestyle.⁴² Weight losses on VLCD are typically greater than the 10% recommended for maximal improvement in NAFLD,^{5,6} but the risk of recurring weight gain is significant and weight loss maintenance is challenging in the long term.⁴³ A low carbohydrate diet may improve NAFLD more than other forms of dietary restriction;²³ however, evidence is mixed and studies comparing different dietary constituents showed no significant difference between low carbohydrate and low fat diets.^{22 35 37}

Exercise interventions on the whole resulted in more modest benefits; all of the trials achieved significant improvements in markers of NAFLD activity regardless of the intervention protocol and one¹⁶ noted that 23% of subjects experienced resolution of NAFLD. Most of the intervention protocols in this review involved 30–60 min of exercise on 3–5 days per week. The data demonstrate aerobic and resistance exercise are both effective. This is an important finding because resistance exercise is more readily available to those of the population most at risk of NAFLD, that is, those with overweight/obesity. Low cardiorespiratory fitness and numerous medical conditions are often concomitant with this population and can preclude aerobic exercise. Therefore performing resistance exercises, relying on body weight alone, can be effective first steps in improving NAFLD.³⁰ However, while statistically significant, the magnitude of the improvement following exercise interventions appears to be less than in dietary interventions.

Combination interventions appear to be the most effective at improving NAFLD. Greater weight loss was

observed in the interventions reviewed, with a range of 4.4–8.8% achieved in these studies.^{32 34 35 38 39} The two longest most intensive intervention trials reported the highest losses in body weight.^{34 38} Al Jiffri *et al*³⁶ did not report body weight but carried out an intervention of 3 months with 100 participants, that resulted in a 15% reduction in BMI; however reasons for this are unclear. At 1200 kcal/day, it was one of the more hypocaloric interventions, with an exercise protocol that was comparable to the other combination interventions. The all-male cohort may be a contributing factor; men lose more weight than women given the same physical activity intervention and are less likely to compensate for energy expended during exercise by increasing energy intake^{45 46} which may result in greater adherence to the dietary component of the intervention. However, the improvement in transaminases that they demonstrated is similar to those in studies achieving lesser weight reductions and 15% BMI losses are unlikely to be achievable in the clinical setting. All of the combination interventions noted a significant improvement in markers of NAFLD; while the interventions were varied in the details, they were broadly similar, measuring improvements in transaminases comparable with those achieved in the weight loss trials. However, transaminase levels do not provide as much information about NAFLD activity as imaging and histology, and are found to be normal in 80% of those with clinically diagnosed NAFLD.⁴⁷

Evidence that weight loss by energy restriction and exercise leads to an improvement in NAFLD, as discussed here, is consistent in that each of the trials included achieved a significant reduction in one or more markers of NAFLD activity. However, further clarification is needed; trials were varied in size and duration, and the heterogeneity of both these and the intervention designs produced equally diverse results. Such diversity limits the extent to which reliable conclusions can be drawn; nevertheless, evidence-based recommendations regarding weight loss and exercise for the management of NAFLD can still be made while acknowledging that some aspects currently remain incompletely understood. The ability to assess patients with NAFLD in the trial setting is enhanced with more advanced imaging techniques and larger RCTs of longer duration are needed to further investigate the effects of lifestyle on NAFLD.

The mechanisms by which dietary restriction and increased exercise improve NAFLD are not fully understood. Weight loss and exercise are already known to improve other components of metabolic syndrome,⁴⁸ so the finding that they also improve the hepatic component of this multiorgan disease is not entirely unexpected. Improvements in NAFLD without weight loss may be due to a change of body composition. During interventions involving exercise, fat mass will be lost and muscle mass will be gained, and these opposing changes can result in no overall effect on total body weight. It is possible that it is the fat loss which is important as

systemic fat loss is associated with a reduction in IHTG,³³ or increased metabolic activity of new muscle mass confers benefits including increased resting metabolic rate.⁴⁹ An alternative hypothesis is that NAFLD and obesity are inflammatory metabolic states and it is the anti-inflammatory effects of the exercise that lead to the improvements seen.^{9 50}

In conclusion, this review has found that interventions involving a combination of dietary restriction and exercise, associated with weight loss, are effective in reducing NAFLD activity, in many cases leading to resolution of the condition. Patients with NAFLD should be advised to aim to lose 5–10% of their total body weight by eating a modestly hypocaloric (–500 kcal per day) diet and engaging in regular exercise for 30–60 min on 3–5 days per week. Dietary composition is probably less important than total energy intake, although a low-carbohydrate diet may be slightly more effective than the alternatives if it is acceptable to the individual. Aerobic and resistance exercise both appear to be equally effective, but less so alone without dietary intervention. Achieving this amount of weight loss is challenging in the existing obesogenic environment and clinical intervention is needed, either in a tier 3 multidisciplinary weight management clinic or via bariatric surgery, which is beyond the scope of this review. Tier 3 clinics are currently underdeveloped to meet existing need and an increase in this type of service is desirable, to support patients and reduce NAFLD progression.

Contributors SK and JBM designed this research. SK and JHS conducted this review, analysed the data and contributed equally to drafting the paper. JBM had primary responsibility for final content.

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

- Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. *Proc Nutr Soc* 2010;69:211–20.
- Farrell GC, Wong VW, Chitturi S. NAFLD in Asia—as common and important as in the West. *Nat Rev Gastroenterol Hepatol* 2013;10:307–18.
- Ekstedt M, Hagström H, Nasr P, *et al.* Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. *Hepatology* 2015;61:1547–54.
- Chalasani N, Younossi Z, Lavine JE, *et al.* The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. *Gastroenterology* 2012;142:1592–609.
- EASL. Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol* 2013;64:1388–402.
- National Guideline C. National Institute for Health and Care Excellence: Guidance. *Non-Alcoholic Fatty Liver Disease: Assessment and Management*. UK: National Institute for Health and Care Excellence, 2016.
- Wong VW-S, Chitturi S, Wong GL-H, *et al.* Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. *Lancet Gastroenterol Hepatol* 2016;1:56–67.
- Musso G, Cassader M, Rosina F, *et al.* Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. *Diabetologia* 2012;55:885–904.
- Ringseis R, Eder K, Mooren FC, *et al.* Metabolic signals and innate immune activation in obesity and exercise. *Exerc Immunol Rev* 2015;21:58–68.
- Hannah WN, Jr, Harrison SA. Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease. *Clin Liver Dis* 2016;20:339–50.
- Orci LA, Gariani K, Oldani G, *et al.* Exercise-based interventions for nonalcoholic fatty liver disease: a meta-analysis and meta-regression. *Clin Gastroenterol Hepatol* 2016;14:1398–411.
- Katsagoni CN, Georgoulis M, Papatheodoridis GV, *et al.* Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: a meta-analysis. *Metabolism* 2017;68:119–32.
- Moher D, Liberati A, Tetzlaff J, *et al.* Reprint—preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Phys Ther* 2009;89:873–80.
- Association AD. ADA Evidence Analysis Manual. Ed IV. 2003.
- Higgins JPT, Green S. *Cochrane handbook for systematic reviews of interventions version 5.1.0*. The Cochrane Collaboration, 2011.
- Bacchi E, Negri C, Targher G, *et al.* Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial). *Hepatology* 2013;58:1287–95.
- Balducci S, Cardelli P, Pugliese L, *et al.* Volume-dependent effect of supervised exercise training on fatty liver and visceral adiposity index in subjects with type 2 diabetes The Italian Diabetes Exercise Study (IDES). *Diabetes Res Clin Pract* 2015;109:355–63.
- Johnson NA, Sachinwalla T, Walton DW, *et al.* Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. *Hepatology* 2009;50:1105–12.
- Keating SE, Hackett DA, Parker HM, *et al.* Effect of aerobic exercise training dose on liver fat and visceral adiposity. *J Hepatol* 2015;63:174–82.
- Lin WY, Wu CH, Chu NF, *et al.* Efficacy and safety of very-low-calorie diet in Taiwanese: a multicenter randomized, controlled trial. *Nutrition* 2009;25:1129–36.
- Yamamoto M, Iwasa M, Iwata K, *et al.* Restriction of dietary calories, fat and iron improves non-alcoholic fatty liver disease. *J Gastroenterol Hepatol* 2007;22:498–503.
- de Luis DA, Aller R, Izaola O, *et al.* Effect of two different hypocaloric diets in transaminases and insulin resistance in nonalcoholic fatty liver disease and obese patients. *Nutr Hosp* 2010;25:730–5.
- Browning JD, Baker JA, Rogers T, *et al.* Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction. *Am J Clin Nutr* 2011;93:1048–52.
- Kani AH, Alavian SM, Esmailzadeh A, *et al.* Effects of a novel therapeutic diet on liver enzymes and coagulating factors in patients with non-alcoholic fatty liver disease: a parallel randomized trial. *Nutrition* 2014;30:814–21.
- Razavi Zade M, Telkabadi MH, Bahmani F, *et al.* The effects of DASH diet on weight loss and metabolic status in adults with non-alcoholic fatty liver disease: a randomized clinical trial. *Liver Int* 2016;36:563–71.
- St George A, Bauman A, Johnston A, *et al.* Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. *J Gastroenterol Hepatol* 2009;24:399–407.
- Hallsworth K, Fattakhova G, Hollingsworth KG, *et al.* Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. *Gut* 2011;60:1278–83.
- Sullivan S, Kirk EP, Mittendorfer B, *et al.* Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. *Hepatology* 2012;55:1738–45.
- Zelber-Sagi S, Buch A, Yeshua H, *et al.* Effect of resistance training on non-alcoholic fatty-liver disease: a randomized-clinical trial. *World J Gastroenterol* 2014;20:4382–92.
- Takahashi A, Abe K, Usami K, *et al.* Simple resistance exercise helps patients with non-alcoholic fatty liver disease. *Int J Sports Med* 2015;36:848–52.
- Cuthbertson DJ, Shojaee-Moradie F, Sprung VS, *et al.* Dissociation between exercise-induced reduction in liver fat and changes in hepatic and peripheral glucose homeostasis in obese patients with non-alcoholic fatty liver disease. *Clin Sci (Lond)* 2016;130:93–104.
- Chen SM, Liu CY, Li SR, *et al.* Effects of therapeutic lifestyle program on ultrasound-diagnosed nonalcoholic fatty liver disease. *J Chin Med Assoc* 2008;71:551–8.

33. Kantartzis K, Thamer C, Peter A, *et al.* High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. *Gut* 2009;58:1281–8.
34. Promrat K, Kleiner DE, Niemeier HM, *et al.* Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. *Hepatology* 2010;51:121–9.
35. Rodriguez-Hernandez H, Cervantes-Huerta M, Rodriguez-Moran M, *et al.* Decrease of aminotransferase levels in obese women is related to body weight reduction, irrespective of type of diet. *Ann Hepatol* 2011;10:486–92.
36. Al-Jiffri O, Al-Sharif FM, Abd El-Kader SM, *et al.* Weight reduction improves markers of hepatic function and insulin resistance in type-2 diabetic patients with non-alcoholic fatty liver. *Afr Health Sci* 2013;13:667–72.
37. Eckard C, Cole R, Lockwood J, *et al.* Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. *Therap Adv Gastroenterol* 2013;6:249–59.
38. Wong VW, Chan RS, Wong GL, *et al.* Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. *J Hepatol* 2013;59:536–42.
39. Aller R, de Luis DA, Izaola O, *et al.* Effect of a high monounsaturated vs high polyunsaturated fat hypocaloric diets in nonalcoholic fatty liver disease. *Eur Rev Med Pharmacol Sci* 2014;18:1041–7.
40. Chitturi S, Farrell GC, Hashimoto E, *et al.* Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. *J Gastroenterol Hepatol* 2007;22:778–87.
41. Wainwright P, Byrne CD. Bidirectional relationships and disconnects between NAFLD and features of the metabolic syndrome. *Int J Mol Sci* 2016;17:367.
42. Tsai AG, Wadden TA. The evolution of very-low-calorie diets: an update and meta-analysis. *Obesity (Silver Spring)* 2006;14:1283–93.
43. Johansson K, Neovius M, Hemmingsson E. Effects of anti-obesity drugs, diet, and exercise on weight-loss maintenance after a very-low-calorie diet or low-calorie diet: a systematic review and meta-analysis of randomized controlled trials. *Am J Clin Nutr* 2014;99:14–23.
44. Keating SE, Hackett DA, George J, *et al.* Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. *J Hepatol* 2012;57:157–66.
45. Williams RL, Wood LG, Collins CE, *et al.* Effectiveness of weight loss interventions—is there a difference between men and women: a systematic review. *Obes Rev* 2015;16:171–86.
46. Stubbs RJ, Sepp A, Hughes DA, *et al.* The effect of graded levels of exercise on energy intake and balance in free-living men, consuming their normal diet. *Eur J Clin Nutr* 2002;56:129–40.
47. Szczepaniak LS, Nurenberg P, Leonard D, *et al.* Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. *Am J Physiol Endocrinol Metab* 2005;288:E462–8.
48. Beavers KM, Nicklas BJ. Effects of lifestyle interventions on inflammatory markers in the metabolic syndrome. *Front Biosci* 2011;3:168–77.
49. Speakman JR, Selman C. Physical activity and resting metabolic rate. *Proc Nutr Soc* 2003;62:621–34.
50. Wensveen FM, Valentić S, Šestan M, *et al.* The “Big Bang” in obese fat: Events initiating obesity-induced adipose tissue inflammation. *Eur J Immunol* 2015;45:2446–56.